查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2136108

人工智慧驅動的藥物發現軟體市場：2026年至2032年全球市場預測

AI Drug Discovery Software Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人工智慧驅動的藥物發現軟體市場將成長至 28.7 億美元，複合年成長率為 9.87%。

主要市場統計數據
基準年 2025 14.8億美元
預計年份：2026年 15.9億美元
預測年份 2032 28.7億美元
複合年成長率 (%) 9.87%

人工智慧藥物發現軟體：概述

人工智慧驅動的藥物發現軟體利用機器學習、深度學習、生成模型、知識圖譜及相關計算技術，在臨床前階段識別標靶、設計分子、進行虛擬篩檢、發現生物標記並做出決策。隨著製藥、生物技術、學術界和公共部門的研究人員尋求更有效率地處理複雜的生物數據並改善實驗優先排序，其作用正在擴大。該軟體的普及應用取決於科學檢驗、數據品質、與實驗室工作流程的整合、監管認可度、網路安全以及能否獲得專業技術人員的支援。

從孤立的工具到整合的藥物發現工作流程

目前的趨勢正從獨​​立的預測應用轉向連結體學、結構生物學、文獻、臨床和實驗數據的協作平台。生成式設計擴大與基於物理的建模、分子模擬和實驗室測試結合使用，而不是取代它們。伴隨這些變化，互通性、可重複性、可解釋性、模型管治和人工審核的重要性也日益凸顯。各機構更重視基於未來實驗檢驗模型、記錄資料來源以及建立知識產權和敏感研究資訊管理系統。

人工智慧加快了優先排序，但檢驗仍然至關重要。

人工智慧可以幫助研究人員識別高維度資料集中的模式、對候選標靶進行排序、提案分子結構、預測特定性質，並實現部分探索和分析的自動化。當模型與可靠的實驗回饋結合時，其累積效應最為顯著，從而能夠實現設計、製造、測試和分析的迭代循環。然而，人工智慧仍存在諸多限制。偏差和不完整的訓練資料、分佈偏移、生物機制的不確定性、不同檢測方法之間的低可移植性以及結果難以重複等問題都會降低其實際應用價值。因此，要使人工智慧產生的輸出能夠作為關鍵研發決策的依據，必須具備該領域的專業知識、實驗室檢驗、透明的效能評估以及適當的監督。

區域洞察：實施狀況反映了研究能力、法規和資料基礎設施。

北美受益於涵蓋製藥、生物技術、學術界、雲端運算和風險投資的深厚生態系統，但監管和數據管治的預期正在影響其應用。在歐洲，重點在於合作研究、隱私保護、可解釋性以及與不斷發展的人工智慧和健康資料框架的契合。亞太地區在計算科學、製造、基因組學和藥物研究方面擁有強大的實力，但不同經濟體的應用模式存在差異。在拉丁美洲，計算生物學和生物技術能力正在發展，但基礎設施、資金籌措的持續性和專業技能正在影響其應用。在中東，對數位健康、生命科學和研究基礎設施的投資正在推進，並透過夥伴關係支持能力建設。在非洲，基因組學、感染疾病研究和本地化藥物開發預計將迎來重大機遇，但網路連接、計算資源獲取、資金籌措和人才培養仍然是關鍵的考慮因素。

團隊洞察：協作塑造標準、資金籌措與應用

東協成員國正在加強數位健康、生物技術和研究能力方面的區域合作，但在基礎設施、監管和人才引進方面仍存在差異。金磚國家在科學、工業和人口規模數據方面擁有相當可觀的能力，但跨境互通性和管治仍然是複雜的挑戰。歐盟高度重視合作研究、隱私、負責任的人工智慧和通用的監管原則。七國集團就先進研究機構、製藥能力、運算資源和可信賴的人工智慧進行政策討論。海灣合作理事會成員國正透過合作投資和國家轉型計畫來推動生命科學和數位能力建設。北約成員國擁有廣泛的研究和安全生態系統，資料保護、韌性、對兩用技術的認知以及可信賴的夥伴關係是其採納決策的關鍵因素。

國家概況：各國能力各異，但互為補充。

澳洲擁有強大的醫學研究和大學實力，並在基因組學和轉化科學領域擁有發展機會。巴西正努力提陞生物技術和計算科學領域的研究能力，同時也努力解決基礎設施和資料取得方面的限制因素。加拿大受益於其成熟的人工智慧和生命科學研究體係以及公共研究網路。中國在製藥、技術和學術領域擁有廣泛的實力，但管治和跨境數據的考量影響其應用。法國、德國、義大利和西班牙擁有強大的研究和醫療保健生態系統，但歐洲的數據和人工智慧要求正在影響其應用。印度擁有多元化的基礎設施和檢驗能力，以及大規模的技術人才隊伍和快速成長的生物技術基礎。日本和韓國擁有先進的技術、製造和生物醫學研究能力。墨西哥正在加強生物技術和研究領域的合作。俄羅斯保持其科學技術實力，但合作、准入和監管條件正在影響其應用。英國在學術界、生物醫學和監管方面擁有強大的專業知識。美國擁有廣泛的研究、技術、製藥和創投能力，並高度重視檢驗、資料管治和負責任的使用。

領導層優先考慮建立可靠的人工智慧發現計劃

領導者不應將人工智慧本身作為最終目標，而應從明確界定的科學和運作挑戰著手。他們還應建立管治的資料基礎設施，涵蓋資料來源、使用者許可、品質控制、存取控制和標準化表示；利用前瞻性檢驗、外部檢驗和決策檢驗來評估模型；並根據需要將軟體與實驗室自動化和回饋迴路整合。跨職能團隊應整合來自藥物化學、生物學、藥理學、資料科學、工程、監管、法律和網路安全等領域的專業知識。此外，組織還應明確模型風險等級、人工核准查核點、文件要求、智慧財產權政策、供應商和互通性標準，以及可衡量的結果，例如實驗優先順序、可重複性、縮短週期時間和科學決策的品質。

調查方法：基於證據的軟體環境評估

本執行摘要採用定性且基於證據的框架來評估人工智慧藥物發現軟體。分析參考了同行評審的科學文獻、監管和政府出版刊物、技術文件、公共研究項目、行業資訊披露以及關於區域研發創新系統的既有資訊。研究結果整合了應用領域、底層技術、工作流程整合、資料管治、檢驗方法、基礎設施、人才和政策環境等方面的資訊。結論僅限於已廣泛記錄的結構性趨勢，不包括市場規模估算、市場佔有率、預測或公司層面的比較。區域、群體和國家層級的觀察結果均結合了研究能力、監管、資金籌措、計算資源和生物醫學數據基礎設施等方面的差異進行解讀。

結論：科學檢驗和信任是永續實施的關鍵。

人工智慧驅動的藥物發現軟體正成為現代科學研究工作流程中的關鍵環節，尤其是在組織複雜證據、確定實驗優先順序以及探索化學和生物學可能性方面。其長期貢獻不僅取決於創新性，還取決於穩健的資料管理實踐、透明的評估、與實驗科學的整合以及負責任的管治。那些將人工智慧定位為經過驗證的決策支援功能，並輔以專家檢驗、可重複的方法論、安全的基礎設施和明確的課責的機構，將更有能力將計算科學的進步轉化為可靠的生物醫學進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：人工智慧驅動的藥物發現軟體市場：按組件分類

  • 專業服務
  • 軟體平台
  • 支援與維護

第8章：人工智慧驅動的藥物發現軟體市場：按人工智慧技術分類

  • 電腦視覺
  • 深度學習
    • 卷積類神經網路
    • 生成式網路與反網路
    • 循環神經網路
  • 機器學習
    • 強化學習
    • 監督式學習
    • 無監督學習
  • 自然語言處理

第9章：人工智慧驅動的藥物發現軟體市場：按治療領域分類

  • 心血管系統
  • 中樞神經系統（CNS）
  • 感染疾病
  • 腫瘤學

第10章：人工智慧驅動的藥物發現軟體市場：按最終用戶分類

  • 學術研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司

第11章：人工智慧驅動的藥物發現軟體市場：按部署模式分類

  • 雲
    • 私有雲端
    • 公共雲端
  • 混合
  • 現場

第12章：人工智慧驅動的藥物發現軟體市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：人工智慧驅動的藥物發現軟體市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人工智慧驅動的藥物發現軟體市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Absci Corp.
  • Atomwise, Inc.
  • BenevolentAI Limited
  • BioSymetrics Corp.
  • Cloud Pharmaceuticals, Inc.
  • Cyclica Inc.
  • Exscientia plc
  • Gritstone bio, Inc.
  • Insilico Medicine, Inc.
  • Owkin, Inc.
  • Recursion Pharmaceuticals, Inc.
  • Schrodinger, Inc.
  • Sensyne Health plc

第17章 主要專家

Product Code: MRR-961F26FD6631

The AI Drug Discovery Software Market is projected to grow by USD 2.87 billion at a CAGR of 9.87% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.48 billion
Estimated Year [2026] USD 1.59 billion
Forecast Year [2032] USD 2.87 billion
CAGR (%) 9.87%

AI Drug Discovery Software: Executive Overview

AI drug discovery software applies machine learning, deep learning, generative models, knowledge graphs, and related computational methods to target identification, molecule design, virtual screening, biomarker discovery, and preclinical decision-making. Its role is expanding as pharmaceutical, biotechnology, academic, and public-sector researchers seek to process complex biological data more efficiently while improving the prioritization of experiments. Adoption depends on scientific validation, data quality, integration with laboratory workflows, regulatory confidence, cybersecurity, and access to specialized technical talent.

From Isolated Tools to Integrated Discovery Workflows

The landscape is shifting from standalone predictive applications toward connected platforms that link omics, structural biology, literature, clinical, and experimental data. Generative design is increasingly used alongside physics-based modeling, molecular simulation, and laboratory testing rather than as a replacement for them. These changes are also increasing the importance of interoperability, reproducibility, explainability, model governance, and human review. Organizations are placing greater emphasis on validating models against prospective experiments, documenting data provenance, and establishing controls for intellectual property and sensitive research information.

Artificial Intelligence Accelerates Prioritization, but Validation Remains Central

Artificial intelligence can help researchers identify patterns across high-dimensional datasets, rank candidate targets, propose molecular structures, predict selected properties, and automate portions of search and analysis. Its cumulative impact is strongest when models are connected to reliable experimental feedback, enabling iterative design-make-test-analyze cycles. Limitations remain significant: biased or incomplete training data, distribution shifts, uncertain biological mechanisms, weak transferability across assays, and difficulty reproducing results can reduce practical value. Accordingly, AI-generated outputs require domain expertise, laboratory confirmation, transparent performance evaluation, and appropriate oversight before they inform consequential development decisions.

Regional Insights: Adoption Reflects Research Capacity, Regulation, and Data Infrastructure

North America benefits from deep pharmaceutical, biotechnology, academic, cloud-computing, and venture ecosystems, while regulatory and data-governance expectations shape deployment. Europe emphasizes collaborative research, privacy, explainability, and alignment with evolving artificial-intelligence and health-data frameworks. Asia-Pacific combines strong capabilities in computational science, manufacturing, genomics, and pharmaceutical research, with adoption patterns varying across economies. Latin America is developing computational biology and biotechnology capacity, while infrastructure, funding continuity, and specialized skills influence implementation. The Middle East is investing in digital health, life sciences, and research infrastructure, with partnerships supporting capability building. Africa presents substantial opportunities in genomics, infectious-disease research, and locally relevant drug development, although connectivity, compute access, funding, and workforce development remain important considerations.

Group Insights: Cooperation Shapes Standards, Funding, and Deployment

ASEAN members are strengthening regional cooperation in digital health, biotechnology, and research capacity, but differ in infrastructure, regulation, and talent availability. BRICS countries bring substantial scientific, industrial, and population-scale data capabilities, while cross-border interoperability and governance remain complex. The European Union places strong emphasis on coordinated research, privacy, responsible AI, and common regulatory principles. G7 economies contribute advanced research institutions, pharmaceutical capabilities, computing resources, and policy discussions on trustworthy AI. GCC members are using coordinated investment and national transformation programs to develop life-science and digital capabilities. NATO countries span a broad research and security ecosystem, making data protection, resilience, dual-use awareness, and trusted collaboration relevant to deployment decisions.

Country Insights: Capabilities Are Uneven but Complementary

Australia combines strong medical research and university capabilities with opportunities in genomics and translational science. Brazil is developing biotechnology and computational research capacity while addressing infrastructure and data-access constraints. Canada benefits from established AI and life-science research communities and public research networks. China has extensive pharmaceutical, technology, and academic capabilities, with governance and cross-border data considerations shaping implementation. France, Germany, Italy, and Spain are supported by substantial research and healthcare ecosystems, while European data and AI requirements influence deployment. India offers a large technical workforce and growing biotechnology base, alongside varied infrastructure and validation capacity. Japan and South Korea combine advanced technology, manufacturing, and biomedical research capabilities. Mexico is strengthening biotechnology and research linkages. Russia retains scientific and technical capabilities, although collaboration, access, and regulatory conditions affect adoption. The United Kingdom has strong academic, biomedical, and regulatory expertise. The United States combines broad research, technology, pharmaceutical, and venture capabilities, with scrutiny focused on validation, data governance, and responsible use.

Action Priorities for Leaders Building Reliable AI Discovery Programs

Leaders should begin with clearly defined scientific and operational problems rather than adopting AI as an end in itself. They should establish governed data foundations covering provenance, consent, quality, access controls, and standardized representations; evaluate models using prospective, external, and decision-relevant validation; and connect software with laboratory automation and feedback loops where appropriate. Cross-functional teams should combine medicinal chemistry, biology, pharmacology, data science, engineering, regulatory, legal, and cybersecurity expertise. Organizations should also define model-risk tiers, human-approval checkpoints, documentation requirements, intellectual-property policies, vendor and interoperability criteria, and measurable outcomes such as experiment prioritization, reproducibility, cycle-time reduction, and scientific decision quality.

Research Methodology: Evidence-Led Assessment of the Software Landscape

This executive summary uses a qualitative, evidence-led framework for assessing AI drug discovery software. The analysis considers peer-reviewed scientific literature, regulatory and governmental publications, technical documentation, public research programs, industry disclosures, and established information on regional research and innovation systems. Findings are synthesized across application areas, enabling technologies, workflow integration, data governance, validation practices, infrastructure, talent, and policy conditions. Claims are limited to broadly documented structural trends; no market estimates, market sizing, market shares, forecasts, or company-specific comparisons are included. Regional, group, and country observations are interpreted in light of differences in research capacity, regulation, funding, computing access, and biomedical data infrastructure.

Conclusion: Scientific Validation and Trust Will Define Sustainable Adoption

AI drug discovery software is becoming an important layer in modern research workflows, particularly for organizing complex evidence, prioritizing experiments, and exploring chemical and biological possibilities. Its long-term contribution will depend less on novelty alone than on robust data practices, transparent evaluation, integration with experimental science, and responsible governance. Organizations that treat AI as a validated decision-support capability-supported by expert review, reproducible methods, secure infrastructure, and clear accountability-will be better positioned to translate computational advances into credible biomedical progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AI Drug Discovery Software Market, by Component

  • 7.1. Introduction
  • 7.2. Professional Services
  • 7.3. Software Platform
  • 7.4. Support And Maintenance

8. AI Drug Discovery Software Market, by Ai Technology

  • 8.1. Introduction
  • 8.2. Computer Vision
  • 8.3. Deep Learning
    • 8.3.1. Convolutional Neural Networks
    • 8.3.2. Generative Adversarial Networks
    • 8.3.3. Recurrent Neural Networks
  • 8.4. Machine Learning
    • 8.4.1. Reinforcement Learning
    • 8.4.2. Supervised Learning
    • 8.4.3. Unsupervised Learning
  • 8.5. Natural Language Processing

9. AI Drug Discovery Software Market, by Therapeutics Area

  • 9.1. Introduction
  • 9.2. Cardiovascular
  • 9.3. Cns
  • 9.4. Infectious Diseases
  • 9.5. Oncology

10. AI Drug Discovery Software Market, by End User

  • 10.1. Introduction
  • 10.2. Academic And Research Institutes
  • 10.3. Biotechnology Companies
  • 10.4. Contract Research Organizations
  • 10.5. Pharmaceutical Companies

11. AI Drug Discovery Software Market, by Deployment Mode

  • 11.1. Introduction
  • 11.2. Cloud
    • 11.2.1. Private Cloud
    • 11.2.2. Public Cloud
  • 11.3. Hybrid
  • 11.4. On-Premises

12. AI Drug Discovery Software Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. AI Drug Discovery Software Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. AI Drug Discovery Software Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Absci Corp.
  • 16.2. Atomwise, Inc.
  • 16.3. BenevolentAI Limited
  • 16.4. BioSymetrics Corp.
  • 16.5. Cloud Pharmaceuticals, Inc.
  • 16.6. Cyclica Inc.
  • 16.7. Exscientia plc
  • 16.8. Gritstone bio, Inc.
  • 16.9. Insilico Medicine, Inc.
  • 16.10. Owkin, Inc.
  • 16.11. Recursion Pharmaceuticals, Inc.
  • 16.12. Schrodinger, Inc.
  • 16.13. Sensyne Health plc

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global AI Drug Discovery Software Market, Years Considered for the Study
  • FIGURE 2. Global AI Drug Discovery Software Market, Research Design
  • FIGURE 3. Global AI Drug Discovery Software Market, Research Framework
  • FIGURE 4. Global AI Drug Discovery Software Market, Data Triangulation
  • FIGURE 5. Global AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global AI Drug Discovery Software Market Size, by Component, 2025 vs 2032 (%)
  • FIGURE 7. Global AI Drug Discovery Software Market Size, by Component, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global AI Drug Discovery Software Market Size, by Ai Technology, 2025 vs 2032 (%)
  • FIGURE 9. Global AI Drug Discovery Software Market Size, by Ai Technology, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global AI Drug Discovery Software Market Size, by Therapeutics Area, 2025 vs 2032 (%)
  • FIGURE 11. Global AI Drug Discovery Software Market Size, by Therapeutics Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global AI Drug Discovery Software Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global AI Drug Discovery Software Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global AI Drug Discovery Software Market Size, by Deployment Mode, 2025 vs 2032 (%)
  • FIGURE 15. Global AI Drug Discovery Software Market Size, by Deployment Mode, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global AI Drug Discovery Software Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global AI Drug Discovery Software Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global AI Drug Discovery Software Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global AI Drug Discovery Software Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global AI Drug Discovery Software Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global AI Drug Discovery Software Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global AI Drug Discovery Software Market Segmentation & Coverage
  • TABLE 2. Global AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 4. Global Professional Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Professional Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Professional Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Software Platform Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Software Platform Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Software Platform Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Support And Maintenance Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Support And Maintenance Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Support And Maintenance Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 14. Global Computer Vision Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Computer Vision Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Computer Vision Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Deep Learning Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Deep Learning Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Deep Learning Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Convolutional Neural Networks Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Convolutional Neural Networks Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Convolutional Neural Networks Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Generative Adversarial Networks Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Generative Adversarial Networks Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Generative Adversarial Networks Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Recurrent Neural Networks Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Recurrent Neural Networks Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Recurrent Neural Networks Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Machine Learning Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Machine Learning Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Machine Learning Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Reinforcement Learning Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Reinforcement Learning Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Reinforcement Learning Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Supervised Learning Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Supervised Learning Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Supervised Learning Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Unsupervised Learning Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Unsupervised Learning Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Unsupervised Learning Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Natural Language Processing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Natural Language Processing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Natural Language Processing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 45. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Cns Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Cns Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Cns Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 58. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 71. Global Cloud Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Cloud Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Cloud Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Private Cloud Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Private Cloud Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Private Cloud Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Public Cloud Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Public Cloud Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Public Cloud Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Hybrid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Hybrid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Hybrid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global On-Premises Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global On-Premises Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global On-Premises Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 96. North America AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. North America AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 98. North America AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 99. North America AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 100. North America AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 101. North America AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 102. North America AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. North America AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 104. North America AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 105. Latin America AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Latin America AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 107. Latin America AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 108. Latin America AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 109. Latin America AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 110. Latin America AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 111. Latin America AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 112. Latin America AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 113. Latin America AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 114. Europe AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Europe AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 116. Europe AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 117. Europe AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 118. Europe AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 119. Europe AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 120. Europe AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. Europe AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 122. Europe AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 123. Middle East AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Middle East AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 125. Middle East AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 126. Middle East AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 127. Middle East AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 128. Middle East AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 129. Middle East AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 130. Middle East AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 131. Middle East AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 132. Africa AI Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 133. Africa AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 134. Africa AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 135. Africa AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 136. Africa AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 137. Africa AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 138. Africa AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. Africa AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 140. Africa AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 141. Global AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 142. ASEAN AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 143. ASEAN AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 144. ASEAN AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 145. ASEAN AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 146. ASEAN AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 147. ASEAN AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 148. ASEAN AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 149. ASEAN AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 150. ASEAN AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 151. GCC AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 152. GCC AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 153. GCC AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 154. GCC AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 155. GCC AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 156. GCC AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 157. GCC AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. GCC AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 159. GCC AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 160. European Union AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 161. European Union AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 162. European Union AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 163. European Union AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 164. European Union AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 165. European Union AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 166. European Union AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 167. European Union AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 168. European Union AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 169. BRICS AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 170. BRICS AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 171. BRICS AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 172. BRICS AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 173. BRICS AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 174. BRICS AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 175. BRICS AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 176. BRICS AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 177. BRICS AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 178. G7 AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 179. G7 AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 180. G7 AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 181. G7 AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 182. G7 AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 183. G7 AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 184. G7 AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. G7 AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 186. G7 AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 187. NATO AI Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 188. NATO AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 189. NATO AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 190. NATO AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 191. NATO AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 192. NATO AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 193. NATO AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. NATO AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 195. NATO AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 196. Global AI Drug Discovery Software Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 197. United States AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 198. United States AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 199. United States AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 200. United States AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 201. United States AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 202. United States AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 203. United States AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 204. United States AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 205. United States AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 206. Canada AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 207. Canada AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 208. Canada AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 209. Canada AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 210. Canada AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 211. Canada AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 212. Canada AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 213. Canada AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 214. Canada AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 215. Mexico AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 216. Mexico AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 217. Mexico AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 218. Mexico AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 219. Mexico AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 220. Mexico AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 221. Mexico AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 222. Mexico AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 223. Mexico AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 224. Brazil AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 225. Brazil AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 226. Brazil AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 227. Brazil AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 228. Brazil AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 229. Brazil AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 230. Brazil AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. Brazil AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 232. Brazil AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 233. United Kingdom AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 234. United Kingdom AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 235. United Kingdom AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 236. United Kingdom AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 237. United Kingdom AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 238. United Kingdom AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 239. United Kingdom AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 240. United Kingdom AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 241. United Kingdom AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 242. Germany AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 243. Germany AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 244. Germany AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 245. Germany AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 246. Germany AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 247. Germany AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 248. Germany AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 249. Germany AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 250. Germany AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 251. France AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 252. France AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 253. France AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 254. France AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 255. France AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 256. France AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 257. France AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 258. France AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 259. France AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 260. Russia AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 261. Russia AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 262. Russia AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 263. Russia AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 264. Russia AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 265. Russia AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 266. Russia AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 267. Russia AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 268. Russia AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 269. Italy AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 270. Italy AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 271. Italy AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 272. Italy AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 273. Italy AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 274. Italy AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 275. Italy AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 276. Italy AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 277. Italy AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 278. Spain AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 279. Spain AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 280. Spain AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 281. Spain AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 282. Spain AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 283. Spain AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 284. Spain AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 285. Spain AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 286. Spain AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 287. China AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 288. China AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 289. China AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 290. China AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 291. China AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 292. China AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 293. China AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. China AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 295. China AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 296. India AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 297. India AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 298. India AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 299. India AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 300. India AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 301. India AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 302. India AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 303. India AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 304. India AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 305. Japan AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 306. Japan AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 307. Japan AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 308. Japan AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 309. Japan AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 310. Japan AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 311. Japan AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 312. Japan AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 313. Japan AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 314. Australia AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 315. Australia AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 316. Australia AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 317. Australia AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 318. Australia AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 319. Australia AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 320. Australia AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 321. Australia AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 322. Australia AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 323. South Korea AI Drug Discovery Software Market Size, 2017-2032 (USD Million)
  • TABLE 324. South Korea AI Drug Discovery Software Market Size, by Component, 2017-2032 (USD Million)
  • TABLE 325. South Korea AI Drug Discovery Software Market Size, by Ai Technology, 2017-2032 (USD Million)
  • TABLE 326. South Korea AI Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
  • TABLE 327. South Korea AI Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
  • TABLE 328. South Korea AI Drug Discovery Software Market Size, by Therapeutics Area, 2017-2032 (USD Million)
  • TABLE 329. South Korea AI Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 330. South Korea AI Drug Discovery Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
  • TABLE 331. South Korea AI Drug Discovery Software Market Size, by Cloud, 2017-2032 (USD Million)
  • TABLE 332. Global AI Drug Discovery Software Market Share, by Key Player, 2025
  • TABLE 333. Global AI Drug Discovery Software Market, Key Experts